28-Oct-2026 20:30:01
JAGSNPHARMDividend
JAGSONPAL Q2 : STANDALONE NET PROFIT UP 0.1% AT ₹12.6 CR (YOY), QOQ N.A.; H1 PAT UP 10.3% (YOY). MIX (ON 1ST LOOK)
• Revenue up 9.3% at ₹81.4 Cr (YOY); consolidated revenue ₹96.4 Cr, up 29% (YOY). • Ebitda at ₹18.5 Cr; margins 22.7% v 24.2% (YOY). • H1 standalone Ebitda up 11.3% at ₹37.5 Cr; H1 PAT up 10.3% at ₹25.8 Cr. • Cash at ₹134.7 Cr after ₹20.8 Cr Aequitas acquisition and 200% dividend. • Caution: Q2 exceptional item ₹20 L relates to Aequitas acquisition.
Jagsonpal Pharmaceuticals Limited
Open attachment